Klotho Neurosciences, Inc. (NASDAQ:KLTO – Get Free Report)’s share price was up 1.7% during mid-day trading on Wednesday . The stock traded as high as $0.37 and last traded at $0.36. Approximately 34,173 shares changed hands during mid-day trading, a decline of 96% from the average daily volume of 838,886 shares. The stock had previously closed at $0.36.
Klotho Neurosciences Stock Performance
The business’s fifty day moving average is $0.43.
Institutional Inflows and Outflows
A hedge fund recently raised its stake in Klotho Neurosciences stock. Geode Capital Management LLC lifted its position in Klotho Neurosciences, Inc. (NASDAQ:KLTO – Free Report) by 122.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 140,606 shares of the company’s stock after purchasing an additional 77,372 shares during the quarter. Geode Capital Management LLC owned about 0.52% of Klotho Neurosciences worth $68,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 20.07% of the company’s stock.
Klotho Neurosciences Company Profile
Klotho Neurosciences, Inc, a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors.
Read More
- Five stocks we like better than Klotho Neurosciences
- How Can Investors Benefit From After-Hours Trading
- 2 Stocks Riding the Dominance of America’s Natural Gas Exports
- Do ETFs Pay Dividends? What You Need to Know
- Buffett’s on the Sidelines – Should You Follow?
- Most Volatile Stocks, What Investors Need to Know
- AST SpaceMobile Stock Surges 17% After Analyst Upgrade
Receive News & Ratings for Klotho Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Klotho Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.